Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Neuroscience Solutions

Neither a doctor nor a teaching hospital

Research payments

$3,382,878

1,154 payments

Through program year 2025, Clinical Neuroscience Solutions is reported as receiving $3,382,878 in research payments, across 1,154 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $68 1
2023 Research $19,815 289
2022 Research $94,476 333
2021 Research $741,670 177
2020 Research $1,144,203 206
2019 Research $1,382,646 148

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $3,124,670 464 payments
  2. Amgen Inc. $186,075 23 payments
  3. Alnylam Pharmaceuticals Inc. $47,622 638 payments
  4. Novartis Pharmaceuticals Corporation $16,974 2 payments
  5. Pfizer Inc. $3,519 9 payments
  6. Biogen, Inc. $1,518 1 payment
  7. ACADIA Pharmaceuticals Inc $1,500 1 payment
  8. Jazz Pharmaceuticals Inc. $800 12 payments
  9. Supernus Pharmaceuticals, Inc. $131 1 payment
  10. Moderna TX, Inc. $68 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $530,746 73 payments
  2. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $434,892 58 payments
  3. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $382,652 49 payments
  4. A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder $313,462 11 payments
  5. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $211,143 28 payments
  6. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $202,968 21 payments
  7. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $162,909 39 payments
  8. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $161,037 50 payments
  9. Medication Overuse Headache Study (MOH)_ $146,184 11 payments
  10. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration 1-week screeningwashout period, 8-week double-blind treatment peri $102,286 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record